Improving CAR T-cell therapy for patients with relapsed lymphoma
Official title: LTBR CARs as next-generation therapies for R/R lymphoma
Funded at New York Genome Center · NIH-11045028 · Data updated 2026-11-12
This study is looking at how to make CAR T-cell therapy work better for people with tough-to-treat diffuse large B-cell lymphoma by exploring a special receptor in T-cells that might help them fight cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Genome Center NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 10, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $810,022 |
| NIH project number | 5R01CA279135-03 |
| Project ID | NIH-11045028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma who have not responded to first-line treatments.
✕Less likely to help
Patients with early-stage lymphoma or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of CAR T-cell therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The team is investigating the role of the lymphotoxin beta receptor (LTBR) in T-cells, which may improve their ability to fight cancer by reducing exhaustion and boosting anti-tumor responses. By analyzing patient samples and conducting functional assays, the researchers aim to develop a more effective CAR T-cell treatment that could lead to better outcomes for patients. If successful, this approach could provide a new avenue for patients who have not responded well to existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T-cell therapies, improving survival rates and quality of life for patients with relapsed lymphoma.
How similar studies have gone: Previous research has shown promise in enhancing CAR T-cell therapies, but the specific approach using LTBR is novel and has not been extensively tested.
Where this research is happening
-
New York Genome Center
New York, United States Active
Researchers
- Principal investigator: Sanjana, Neville — New York Genome Center
- Study coordinator: Sanjana, Neville
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.